A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Is this Study for You?

Let's Get Started!




Highlands Ranch Hospital
Lone Tree Medical Center
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Marie Wood

Marie Wood

Study ID

Protocol Number: 23-1465

More information available at ClinicalTrials.gov: NCT05633654


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers